Our mission is to position ophthalmologists on the leading edge of patient care by offering groundbreaking solutions for Age-Related Macular Degeneration (AMD).
As leaders in the field, you’re at the forefront of patient care, constantly seeking innovative solutions to enhance outcomes. At Compass HealthAI, we recognize your dedication and share your commitment to excellence.
Compass’ initial breakthrough is a revolutionary and patented approach that is proving to make a substantial improvement in the vision and quality of life in patients suffering from AMD.
Our patented Ophthalmic Laser and treatment protocol provide a minimally invasive procedure that immediately increases visual acuity.
Approved by Health Canada, ophthalmologists have treated hundreds of patients with AMD.
Contact UsThe science supporting our breakthrough technology is exciting!
Through a procedure that spans 0.18 seconds, light is redirected to a healthy part of the retina not impacted by macular degeneration.
Compass’ Ophthalmic Laser is indicated for the improvement of best spectacle-corrected distance visual acuity (CDVA) and/or best spectacle-corrected near visual acuity (CNVA) in patient eyes with age-related macular degeneration (AMD) and with moderate to profound vision loss, with corrected distance visual acuity (CDVA) between 20/63 (decimal = 0.317; logMAR = 0.50) to 20/800 (decimal = 0.025; logMAR = 1.60) in the eye(s) to be treated.
Patients who meet all of the following criteria are eligible to receive treatments:
Male or Female
Any race
Patient is at least 55 years old.
Patient has diagnosed age-related macular degeneration in one or both eyes, as verified by a complete ocular examination by a retina specialist; the full ocular examination should be part of the patient's file.
Patient has moderate to profound vision impairment due to age-related macular degeneration with best spectacle-corrected distance visual acuity (CDVA) of 20/63 or worse (decimal ≤ 0.317; logMAR ≥ 0.50) in one or both eyes to be treated.
Patient has CDVA of 20/800 or better (decimal ≥ 0.025; logMAR ≤ 1.60) in one or both eyes to be treated.
Patient has normal corneal surface topography on videokeratography (i.e., without distorted or unclear corneal mires) in one or both eyes to be treated.
Patient is not a contact lens (CL) wearer.
Patient is willing and able to comply with all examinations.
Patient must be competent to sign an informed consent form before study entry.
Patients who meet any of the following criteria are not eligible to receive treatments:
Corneal disease or disorder in either eye;
Geographic atrophy and/or other retinal pathology in either eye that completely affects the entire 10° (3 mm diameter) of the retina centered on the foveola (as evaluated by optical coherence tomography);
Gonzalez-Markowitz chart Potential Visual Acuity (PVA) that is not improved by at least two lines compared to CDVA; and
Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for treatment.
Compass has developed an entire platform around our laser technology to offer a turnkey solution to clinics.
Patient Engagement
Compass provides all material to engage patients to ensure your clinic generates real awareness within your patient base. This includes ideal patient profiles as well as concise information that can be shared with patients directly.
Order to Cash
Experience our turnkey solution for patient data collection and payment. Compass provides a seamless interface for patients to schedule and pay for treatments at your clinic.
Patient Screening
Compass provides a complete list of test required for patient screening. Depending on your preference, we can also provide references to supporting clinics to perform screening as appropriate.
Device & Procedure Training
Compass’ ophthalmic laser treatment is straight forward. We provide complete training for the treatment and all supporting processes from payment to treatment.
Follow Up
Compass provides a clear guideline for follow up care for the on-going support of patients.
For neovascular AMD patients, those that have received the laser treatment are far more likely to continue aVEGF to preserve their new found freedom.
We understand the importance of collaboration in shaping the future of patient care. By partnering with Compass HealthAI, you gain access to cutting-edge technologies and resources that empower you to deliver exceptional care to your patients. Together, we can lead the way in redefining patient care standards and setting new benchmarks for excellence.
Unrivaled Expertise: With a proven track record of success, Compass HealthAI brings unparalleled expertise to the table.
Our patented solution represents the epitome of innovation, setting new benchmarks in AMD treatment.
We value collaboration and view ophthalmologists as essential partners in achieving optimal patient outcomes.
Join forces with Compass HealthAI to elevate your practice to new heights of excellence and position yourself as a leader in patient care.
Together, let's pave the way for a brighter future in patient care.